Figure 2.

Classification of Sézary patients using qPCR data. Data shown are for analysis using FLDA. Scores for patient samples are shown in panel A, and controls are shown in panel B. The dataset consists of 125 samples: 56 from 49 patients with erythrodermic CTCL and 69 from 65 controls. The controls are untreated (UT), Th1 skewed (Th1), Th2 skewed (Th2), and PHA treated (PHA). The patient samples are sorted according to the blood tumor burden (5% to 99%) indicated by the last 2 digits of the label. Patients in whom percent Sézary was not available are indicated as “NA.” A positive score indicates the sample is classified as a patient; a negative score indicates the sample is classified as a control. The height of each bar represents the average score that a given sample received, when tested approximately 100 times, during 1000 random resamplings. The error bars indicate the standard deviation in the generated set of scores for the sample. Sézary samples (S) are followed by a 3-digit patient donor code. Serial samples taken at different times from the same patient are indicated by an additional number (ie, S151.1, S151.4) and followed by the percent Sézary cells present. None of the controls was sampled more than once, but samples from donors C017, C018, and C019 were also skewed to the Th1 (C017, C018, C019) and Th2 (C017) phenotype. The classifier has a sensitivity of 86% and a specificity of 95% on this dataset.